{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:00:56Z","timestamp":1792036856561,"version":"4.4.0"},"reference-count":219,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013061","name":"Jilin Scientific and Technological Development Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.blre.2025.101256","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T11:09:59Z","timestamp":1736593799000},"page":"101256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma"],"prefix":"10.1016","volume":"70","author":[{"given":"Tingting","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7835","key":"10.1016\/j.blre.2025.101256_bb0005","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1038\/d41586-020-03223-2","article-title":"Multiple myeloma","volume":"587","author":"Outlook","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.blre.2025.101256_bb0010","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2025.101256_bb0015","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0020","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.blre.2025.101256_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.05.007","article-title":"Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease","volume":"41","author":"Dang","year":"2023","journal-title":"Cancer Cell"},{"issue":"10272","key":"10.1016\/j.blre.2025.101256_bb0030","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0035","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-023-01489-3","article-title":"Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 annual meeting","volume":"16","author":"Zhao","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0040","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0045","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-023-01479-5","article-title":"BCMA-targeted CAR-T cell therapies in relapsed and\/or refractory multiple myeloma: latest updates from 2023 ASCO annual meeting","volume":"16","author":"Wu","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101256_bb0050","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41375-023-01883-3","article-title":"Preclinical discovery and initial clinical data of WVT078, a BCMA \u00d7 CD3 bispecific antibody","volume":"37","author":"Raab","year":"2023","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.blre.2025.101256_bb0055","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.3324\/haematol.2022.281772","article-title":"Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study","volume":"108","author":"Talbot","year":"2023","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.blre.2025.101256_bb0060","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41408-021-00592-3","article-title":"\u201creal-life\u201d data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience","volume":"11","author":"Vaxman","year":"2021","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.blre.2025.101256_bb0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.blre.2025.101256_bb0070","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0075","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.blre.2025.101256_bb0080","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101256_bb0085","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S2152-2650(22)00278-6","article-title":"OAB-005: point mutations in BCMA extracellular domain mediate resistance to BCMA targeting immune therapies","volume":"22","author":"Lee","year":"2022","journal-title":"Clin Lymph Myeloam Leu"},{"key":"10.1016\/j.blre.2025.101256_bb0090","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front Immunol"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2025.101256_bb0095","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1182\/blood-2019-129582","article-title":"Response to Bcma CAR-T cells correlates with pretreatment target antigen density and is improved by small molecule inhibition of gamma secretase","volume":"134","author":"Green","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101256_bb0100","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.blre.2025.101256_bb0105","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000691","article-title":"Anti-BCMA CAR T-cell therapy: changing the natural history of multiple myeloma","volume":"6","author":"Puertas","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.blre.2025.101256_bb0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-137650","article-title":"Cite-seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR-T or bites immunotherapy","volume":"136","author":"Leblay","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101256_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev"},{"issue":"11","key":"10.1016\/j.blre.2025.101256_bb0120","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1002\/j.1460-2075.1992.tb05482.x","article-title":"A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma","volume":"11","author":"La\u00e2bi","year":"1992","journal-title":"EMBO J"},{"issue":"2","key":"10.1016\/j.blre.2025.101256_bb0125","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V81.2.454.454","article-title":"Subtractive cDNA cloning of a novel member of the Ig gene superfamily expressed at high levels in activated B lymphocytes","volume":"81","author":"Kozlow","year":"1993","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2025.101256_bb0130","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/nar\/22.7.1147","article-title":"The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed","volume":"22","author":"Laabi","year":"1994","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.blre.2025.101256_bb0135","doi-asserted-by":"crossref","first-page":"735","DOI":"10.4049\/jimmunol.149.2.735","article-title":"A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily","volume":"149","author":"Zhou","year":"1992","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.blre.2025.101256_bb0140","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","article-title":"The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily","volume":"10","author":"Madry","year":"1998","journal-title":"Int Immunol"},{"issue":"3","key":"10.1016\/j.blre.2025.101256_bb0145","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4049\/jimmunol.165.3.1322","article-title":"TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase","volume":"165","author":"Hatzoglou","year":"2000","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.blre.2025.101256_bb0150","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/cbf.3169","article-title":"Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways","volume":"34","author":"Shen","year":"2016","journal-title":"Cell Biochem Funct"},{"issue":"8","key":"10.1016\/j.blre.2025.101256_bb0155","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.blre.2025.101256_bb0160","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2025.101256_bb0165","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1158\/1535-7163.MCT-07-0464","article-title":"Antibody targeting of B-cell maturation antigen on malignant plasma cells","volume":"6","author":"Ryan","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0170","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.blre.2025.101256_bb0175","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1128\/MCB.21.12.4067-4074.2001","article-title":"B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses","volume":"21","author":"Xu","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"8","key":"10.1016\/j.blre.2025.101256_bb0180","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.blre.2025.101256_bb0185","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.173.2.807","article-title":"B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells","volume":"173","author":"Ng","year":"2004","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.blre.2025.101256_bb0190","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.3892\/ol.2017.6528","article-title":"Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance","volume":"14","author":"Pan","year":"2017","journal-title":"Oncol Lett"},{"issue":"13","key":"10.1016\/j.blre.2025.101256_bb0195","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","article-title":"Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment","volume":"66","author":"Tai","year":"2006","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0200","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-019-0796-4","article-title":"APRIL and BAFF: novel biomarkers for central nervous system lymphoma","volume":"12","author":"Mulazzani","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101256_bb0205","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/bi048227k","article-title":"Selectivity of BAFF\/BLyS and APRIL for binding to the TNF family receptors BAFFR\/BR3 and BCMA","volume":"44","author":"Day","year":"2005","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.blre.2025.101256_bb0210","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-0609.2009.01262.x","article-title":"APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop","volume":"83","author":"Moreaux","year":"2009","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2025.101256_bb0215","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00277-013-1924-9","article-title":"BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma","volume":"93","author":"Bolkun","year":"2014","journal-title":"Ann Hematol"},{"issue":"13","key":"10.1016\/j.blre.2025.101256_bb0220","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0960-9822(00)00566-2","article-title":"Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI","volume":"10","author":"Marsters","year":"2000","journal-title":"Curr Biol"},{"issue":"6781","key":"10.1016\/j.blre.2025.101256_bb0225","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0230","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1084\/jem.192.1.129","article-title":"BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population","volume":"192","author":"Thompson","year":"2000","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.blre.2025.101256_bb0235","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.4049\/jimmunol.173.4.2245","article-title":"TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology","volume":"173","author":"Sasaki","year":"2004","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.blre.2025.101256_bb0240","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1074-7613(03)00025-6","article-title":"Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor","volume":"18","author":"Seshasayee","year":"2003","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.blre.2025.101256_bb0245","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.4049\/jimmunol.178.9.5612","article-title":"Divergent effects of BAFF on human memory B cell differentiation into Ig-secreting cells","volume":"178","author":"Darce","year":"2007","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.blre.2025.101256_bb0250","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","article-title":"The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature","volume":"106","author":"Moreaux","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101256_bb0255","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41375-018-0242-6","article-title":"APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications","volume":"33","author":"Tai","year":"2019","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2025.101256_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.10.097","article-title":"IRF4 activity is required in established plasma cells to regulate gene transcription and mitochondrial homeostasis","volume":"29","author":"Low","year":"2019","journal-title":"Cell Rep"},{"issue":"7","key":"10.1016\/j.blre.2025.101256_bb0265","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/s41375-020-01078-0","article-title":"The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival","volume":"35","author":"Fedele","year":"2021","journal-title":"Leukemia"},{"issue":"7201","key":"10.1016\/j.blre.2025.101256_bb0270","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.blre.2025.101256_bb0275","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1007\/s11033-010-0028-z","article-title":"B-lymphocyte-induced maturation protein1 up-regulates the expression of B-cell maturation antigen in mouse plasma cells","volume":"37","author":"Deng","year":"2010","journal-title":"Mol Biol Rep"},{"issue":"3","key":"10.1016\/j.blre.2025.101256_bb0280","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.blre.2025.101256_bb0285","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2025.101256_bb0290","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11523-019-00666-0","article-title":"Plasma B-cell maturation antigen levels are elevated and correlate with disease activity in patients with chronic lymphocytic leukemia","volume":"14","author":"Udd","year":"2019","journal-title":"Target Oncol"},{"issue":"14","key":"10.1016\/j.blre.2025.101256_bb0295","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.7150\/jca.15966","article-title":"Involvement of BAFF and APRIL in resistance to apoptosis of acute myeloid leukemia","volume":"7","author":"Bolkun","year":"2016","journal-title":"J Cancer"},{"issue":"6","key":"10.1016\/j.blre.2025.101256_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020787","article-title":"Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival","volume":"6","author":"Maia","year":"2011","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.blre.2025.101256_bb0305","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ymthe.2018.06.012","article-title":"CAR T cells with enhanced sensitivity to B cell maturation antigen for the targeting of B cell non-Hodgkin\u2019s lymphoma and multiple myeloma","volume":"26","author":"Bluhm","year":"2018","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.blre.2025.101256_bb0310","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1016\/j.blre.2025.101256_bb0315","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2006-04-015958","article-title":"Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL","volume":"109","author":"Chiu","year":"2007","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101256_bb0320","first-page":"2755","article-title":"B-cell maturation antigen is exclusively expressed in a wide range of B-cell and plasma cell neoplasm and in a potential therapeutic target for Bcma directed therapies","volume":"30","author":"Khattar","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2025.101256_bb0325","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.3892\/ol.2016.5095","article-title":"APRIL, BCMA and TACI proteins are abnormally expressed in non-small cell lung cancer","volume":"12","author":"Dou","year":"2016","journal-title":"Oncol Lett"},{"issue":"10","key":"10.1016\/j.blre.2025.101256_bb0330","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.4049\/jimmunol.1102891","article-title":"APRIL binding to BCMA activates a JNK2-FOXO3-GADD45 pathway and induces a G2\/M cell growth arrest in liver cells","volume":"189","author":"Notas","year":"2012","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.blre.2025.101256_bb0335","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1210\/en.2011-1504","article-title":"B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies","volume":"153","author":"Alexaki","year":"2012","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.blre.2025.101256_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083250","article-title":"BAFF, APRIL, TWEAK, BCMA, TACI and Fn14 proteins are related to human glioma tumor grade: immunohistochemistry and public microarray data meta-analysis","volume":"8","author":"Pelekanou","year":"2013","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.blre.2025.101256_bb0345","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/carcin\/bgv020","article-title":"APRIL promotes breast tumor growth and metastasis and is associated with aggressive basal breast cancer","volume":"36","author":"Garc\u00eda-Castro","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.blre.2025.101256_bb0350","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell\u2013engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0355","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2025.101256_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215949","article-title":"BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"553","author":"Yang","year":"2023","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.blre.2025.101256_bb0365","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/BS9.0000000000000173","article-title":"CAR-T cell therapy: where are we now, and where are we heading?","volume":"5","author":"Wang","year":"2023","journal-title":"Blood Sci"},{"issue":"4","key":"10.1016\/j.blre.2025.101256_bb0370","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00277-023-05444-7","article-title":"BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and\/or refractory multiple myeloma","volume":"103","author":"Fang","year":"2024","journal-title":"Ann Hematol"},{"issue":"13","key":"10.1016\/j.blre.2025.101256_bb0375","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.blre.2025.101256_bb0380","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.blre.2025.101256_bb0385","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/s41587-020-00757-8","article-title":"Specter of eye toxicity looms over BCMA-targeted therapy","volume":"38","author":"Dolgin","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.blre.2025.101256_bb0390","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/BS9.0000000000000148","article-title":"CAR-T cell therapy in myeloma: hopes and hurdles","volume":"5","author":"Harousseau","year":"2023","journal-title":"Blood Sci"},{"issue":"14","key":"10.1016\/j.blre.2025.101256_bb0395","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2025.101256_bb0400","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0405","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","article-title":"Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing","volume":"12","author":"Li","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"10.1016\/j.blre.2025.101256_bb0410","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/ejh.13380","article-title":"B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: a meta-analysis","volume":"104","author":"Gagelmann","year":"2020","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2025.101256_bb0415","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0420","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in multiple myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.blre.2025.101256_bb0425","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"issue":"7","key":"10.1016\/j.blre.2025.101256_bb0430","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/imcb.12254","article-title":"Chimeric antigen receptor T cell persistence and memory cell formation","volume":"97","author":"McLellan","year":"2019","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0435","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-022-01244-0","article-title":"Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells","volume":"15","author":"Tan","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0440","doi-asserted-by":"crossref","first-page":"20","DOI":"10.33696\/cancerimmunol.6.080","article-title":"Enhancing the efficacy of CAR-T cell therapy: a comprehensive exploration of cellular strategies and molecular dynamics","volume":"6","author":"Baysal","year":"2024","journal-title":"J Cancer Immunol (Wilmington)"},{"key":"10.1016\/j.blre.2025.101256_bb0445","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241245194","article-title":"Treatment of multiple myeloma: what is the impact on T-cell function?","volume":"15","author":"Li","year":"2024","journal-title":"Ther Adv Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101256_bb0450","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood-2018-99-115319","article-title":"Clinical predictors of T cell fitness for CAR T cell manufacturing and efficacy in multiple myeloma","volume":"132","author":"Dancy","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101256_bb0455","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.568056","article-title":"Altered T-lymphocyte biology following high-dose melphalan and autologous stem cell transplantation with implications for adoptive T-cell therapy","volume":"10","author":"Mika","year":"2020","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.blre.2025.101256_bb0460","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jha2.479","article-title":"CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment","volume":"3","author":"Abecassis","year":"2022","journal-title":"EJHaem"},{"issue":"27","key":"10.1016\/j.blre.2025.101256_bb0465","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.blre.2025.101256_bb0470","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.blre.2025.101256_bb0475","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2025.101256_bb0480","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2025.101256_bb0485","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.2023021221","article-title":"CAR T-cell therapy in multiple myeloma: mission accomplished?","volume":"143","author":"Rasche","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2025.101256_bb0490","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/jamaoncol.2024.2172","article-title":"B-cell maturation antigen\/CD19 dual-targeting immunotherapy in newly diagnosed multiple myeloma","volume":"10","author":"Qiang","year":"2024","journal-title":"JAMA Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101256_bb0495","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1182\/blood-2018-99-115351","article-title":"Aged CAR T cells exhibit enhanced cytotoxicity and effector function but shorter persistence and less memory-like phenotypes","volume":"132","author":"Kotani","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2025.101256_bb0500","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.blre.2025.101256_bb0505","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1172\/JCI24480","article-title":"Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells","volume":"115","author":"Gattinoni","year":"2005","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0510","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nm.4241","article-title":"T memory stem cells in health and disease","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.blre.2025.101256_bb0515","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc3322","article-title":"Paths to stemness: building the ultimate antitumour T cell","volume":"12","author":"Gattinoni","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.blre.2025.101256_bb0520","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jtct.2023.11.014","article-title":"PD1(+)TIGIT(+)2B4(+)KLRG1(+) cells might underlie T cell dysfunction in patients treated with BCMA-directed chimeric antigen receptor T cell therapy","volume":"30","author":"Mishra","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"27","key":"10.1016\/j.blre.2025.101256_bb0525","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1073\/pnas.0503726102","article-title":"Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells","volume":"102","author":"Klebanoff","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0530","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1172\/JCI81217","article-title":"Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy","volume":"126","author":"Klebanoff","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0535","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","volume":"118","author":"Berger","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101256_bb0540","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-024-02339-4","article-title":"A CAR enhancer increases the activity and persistence of CAR T cells","author":"Rakhshandehroo","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.1016\/j.blre.2025.101256_bb0545","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2025.101256_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2022.09.013","article-title":"Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells","volume":"40","author":"Zhang","year":"2022","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.blre.2025.101256_bb0555","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","article-title":"PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells","volume":"32","author":"Zheng","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0560","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-021-01117-y","article-title":"Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion","volume":"14","author":"Zhang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2025.101256_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0570","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-023-01504-7","article-title":"Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy","volume":"16","author":"Bulliard","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2025.101256_bb0575","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","article-title":"Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma","volume":"7","author":"Frigault","year":"2023","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.blre.2025.101256_bb0580","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2025.101256_bb0585","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1172\/JCI86437","article-title":"BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models","volume":"126","author":"Kagoya","year":"2016","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.blre.2025.101256_bb0590","article-title":"Inhibition of calcium signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via SOCE-calcineurin-NFAT and glycolysis pathways","volume":"9","author":"Shao","year":"2022","journal-title":"Adv Sci (Weinh)"},{"issue":"7","key":"10.1016\/j.blre.2025.101256_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101085","article-title":"A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory\/relapsed B cell lymphoma","volume":"14","author":"Liu","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.blre.2025.101256_bb0600","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0605","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12967-024-05772-w","article-title":"BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed\/refractory multiple myeloma","volume":"22","author":"Yan","year":"2024","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.blre.2025.101256_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114065","article-title":"Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway","volume":"43","author":"Zhu","year":"2024","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.blre.2025.101256_bb0615","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.blre.2025.101256_bb0620","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/cancers13040625","article-title":"The immune microenvironment in multiple myeloma: friend or foe?","volume":"13","author":"Lopes","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.blre.2025.101256_bb0625","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0630","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-022-01234-2","article-title":"Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma","volume":"15","author":"Swamydas","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.blre.2025.101256_bb0635","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0640","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol Rev"},{"issue":"13","key":"10.1016\/j.blre.2025.101256_bb0645","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1158\/1078-0432.CCR-20-2188","article-title":"Bone marrow mesenchymal stromal cells can render multiple myeloma cells resistant to cytotoxic machinery of CAR T cells through inhibition of apoptosis","volume":"27","author":"Holthof","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.blre.2025.101256_bb0650","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1182\/blood.2021012811","article-title":"Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma","volume":"139","author":"Sakemura","year":"2022","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2025.101256_bb0655","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2019-125818","article-title":"The impact and modulation of microenvironment-induced immune resistance against CAR T cell and antibody treatments in multiple myeloma","volume":"134","author":"Holthof","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101256_bb0660","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3389\/fonc.2019.00322","article-title":"A metabolism toolbox for CAR T therapy","volume":"9","author":"Xu","year":"2019","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.blre.2025.101256_bb0665","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","article-title":"Metabolism of immune cells in cancer","volume":"20","author":"Leone","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2025.101256_bb0670","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3389\/fimmu.2019.01719","article-title":"T cell dysfunction in cancer immunity and immunotherapy","volume":"10","author":"Xia","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.blre.2025.101256_bb0675","first-page":"100","article-title":"Targeting metabolism to improve CAR-T cell immunotherapy","volume":"1","author":"Hou","year":"2022","journal-title":"Clin Cancer Bull"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0680","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12943-024-02079-8","article-title":"Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy","volume":"23","author":"Xia","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.blre.2025.101256_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.12.520","article-title":"Enhancing anti-BCMA CAR-T cell activity with sIL-15 cytokine: evaluation of its impact on in vitro cytotoxicity, cytokine production, and T cell exhaustion","volume":"30","author":"Mitsugi","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"26","key":"10.1016\/j.blre.2025.101256_bb0690","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1182\/blood.2021012811","article-title":"Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma","volume":"139","author":"Sakemura","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101256_bb0695","article-title":"Combination cancer immunotherapies: emerging treatment strategies adapted to the tumor microenvironment","volume":"14(670):eabo3605","author":"Kirchhammer","year":"2022","journal-title":"Sci Transl Med"},{"issue":"13","key":"10.1016\/j.blre.2025.101256_bb0700","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2025.101256_bb0705","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2025.101256_bb0710","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.blre.2025.101256_bb0715","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T cell\u2013engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.blre.2025.101256_bb0720","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1182\/bloodadvances.2023010025","article-title":"Monoallelic deletion of BCMA is a frequent feature in multiple myeloma","volume":"7","author":"Samur","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2025.101256_bb0725","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101256_bb0730","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"10.1016\/j.blre.2025.101256_bb0735","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-15-2224","article-title":"Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma","volume":"22","author":"Sanchez","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.blre.2025.101256_bb0740","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101256_bb0745","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","article-title":"Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells","volume":"81","author":"Chen","year":"2019","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.blre.2025.101256_bb0750","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.blre.2025.101256_bb0755","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3324\/haematol.2022.281339","article-title":"All-trans retinoic acid works synergistically with the \u03b3-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells","volume":"108","author":"Garc\u00eda-Guerrero","year":"2023","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.blre.2025.101256_bb0760","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1470-2045(23)00283-8","article-title":"\u03b3-Secretase inhibitors plus anti-BCMA chimeric antigen receptor T cells","volume":"24","author":"Mussetti","year":"2023","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.blre.2025.101256_bb0765","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-022-00716-3","article-title":"\u03b3-Secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation","volume":"12","author":"Chen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"7750","key":"10.1016\/j.blre.2025.101256_bb0770","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.blre.2025.101256_bb0775","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2025.101256_bb0780","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1182\/blood-2023-187349","article-title":"Regulation of BCMA by the ubiquitin proteasome system enables optimization of BCMA targeting therapies in multiple myeloma","volume":"142","author":"Rieger","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2025.101256_bb0785","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood.2022016928","article-title":"Reverse translational studies inform dual-targeted CAR T-cell design","volume":"140","author":"Rouce","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0790","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.blre.2025.101256_bb0795","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free sleeping beauty gene transfer to treat multiple myeloma","volume":"28","author":"Prommersberger","year":"2021","journal-title":"Gene Ther"},{"issue":"10","key":"10.1016\/j.blre.2025.101256_bb0800","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"issue":"20","key":"10.1016\/j.blre.2025.101256_bb0805","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101256_bb0810","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0815","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.blre.2025.101256_bb0820","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"de Larrea","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.blre.2025.101256_bb0825","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1182\/blood-2021-148543","article-title":"Bispecific CAR-T cells targeting both BCMA and CD24: a potentially treatment approach for multiple myeloma","volume":"138","author":"Sun","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101256_bb0830","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1182\/blood-2021-154025","article-title":"Dual chimeric antigen receptor approach combining novel tumor targeting strategies circumvents antigen escape in multiple myeloma","volume":"138","author":"Reiser","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0835","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1038\/s41467-023-43416-7","article-title":"Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma","volume":"14","author":"Larson","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb0840","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41467-021-27853-w","article-title":"A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers","volume":"13","author":"Wong","year":"2022","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.blre.2025.101256_bb0845","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2025.101256_bb0850","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.blre.2025.101256_bb0855","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.2023022499","article-title":"BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety and resistance mechanisms","volume":"143","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"10396","key":"10.1016\/j.blre.2025.101256_bb0860","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.blre.2025.101256_bb0865","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/bloodadvances.2023012354","article-title":"Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications","volume":"8","author":"Letouz\u00e9","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.blre.2025.101256_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101256_bb0875","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2022-162709","article-title":"Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): correlative analyses from MajesTEC-1","volume":"140","author":"Cortes-Selva","year":"2022","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.blre.2025.101256_bb0880","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1182\/bloodadvances.2020002565","article-title":"AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys","volume":"4","author":"Goldstein","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101256_bb0885","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatmentnaive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.blre.2025.101256_bb0890","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1158\/2326-6066.CIR-19-0148","article-title":"Lessons learned from checkpoint blockade targeting PD-1 in multiple myeloma","volume":"7","author":"Lesokhin","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.blre.2025.101256_bb0895","doi-asserted-by":"crossref","first-page":"7054","DOI":"10.1182\/blood-2022-157987","article-title":"Synergistic antitumor activity of alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA 2 + 1 T cell engager (TCE), and celmod agents in multiple myeloma (MM) preclinical models","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101256_bb0900","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3390\/cancers15061819","article-title":"Bispecific antibodies in multiple myeloma: opportunities to enhance efficacy and improve safety","volume":"15","author":"Swan","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2025.101256_bb0905","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.blre.2025.101256_bb0910","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2025.101256_bb0915","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2022-159711","article-title":"Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a phase1b, multicohort study","volume":"140","author":"Searle","year":"2022","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2025.101256_bb0920","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood-2024-206003","article-title":"Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) trial","volume":"144","author":"Raab","year":"2024","journal-title":"Blood"},{"issue":"Suppl1","key":"10.1016\/j.blre.2025.101256_bb0925","doi-asserted-by":"crossref","first-page":"10148","DOI":"10.1182\/blood-2022-160173","volume":"140","author":"Krishnan","year":"2022","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2025.101256_bb0930","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1182\/blood-2022-157713","article-title":"REGN5458, a BCMAxCD3 bispecific antibody, in a phase Ib multi-cohort study of combination regimens for patients with relapsed\/refractory multiple myeloma","volume":"140","author":"Otero","year":"2022","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2025.101256_bb0935","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2024-205608","volume":"144","author":"Zamagni","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2025.101256_bb0940","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101256_bb0945","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/01.HS9.0000843624.82943.92","article-title":"Noval combination immunotherapy for the treatment of relapsed\/refractory multiple myeloma: updated phase 1B results for Talquetamab (a GPRC5D X CD3 bispecific antibody) in combination with daratumumab","volume":"6","author":"van de Donk","year":"2022","journal-title":"HemaSphere"},{"issue":"20","key":"10.1016\/j.blre.2025.101256_bb0950","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-12-3676","article-title":"Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance","volume":"19","author":"de Haart","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.blre.2025.101256_bb0955","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.7150\/thno.81494","article-title":"When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy","volume":"13","author":"Tapia-Galisteo","year":"2023","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.blre.2025.101256_bb0960","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.blre.2025.101256_bb0965","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Firestone","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2025.101256_bb0970","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.3390\/ph16111628","article-title":"Novel immunotherapies and combinations: the future landscape of multiple myeloma treatment","volume":"16","author":"Mor\u00e8","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2025.101256_bb0975","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1182\/blood-2023-190517","article-title":"Immune and genome profiling of myeloma patients treated with sequential immunotherapies reveal differential non-overlapping mechanisms of resistance","volume":"142","author":"Lee","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2025.101256_bb0980","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat Cancer"},{"issue":"5","key":"10.1016\/j.blre.2025.101256_bb0985","first-page":"493","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma Nat","volume":"1","author":"Zavidij","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2025.101256_bb0990","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2025.101256_bb0995","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s43018-024-00821-1","article-title":"ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells","volume":"5","author":"Carretero-Iglesia","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.blre.2025.101256_bb1000","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2025.101256_bb1005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.blre.2025.101256_bb1010","doi-asserted-by":"crossref","first-page":"9674","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.blre.2025.101256_bb1015","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"10.1016\/j.blre.2025.101256_bb1020","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3390\/cancers15041278","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"15","author":"Abelman","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.blre.2025.101256_bb1025","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"10.1016\/j.blre.2025.101256_bb1030","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1158\/1078-0432.CCR-21-1621","article-title":"BCMA-specific ADC MEDI2228 and Daratumumab induce synergistic myeloma cytotoxicity via IFN-driven immune responses and enhanced CD38 expression","volume":"27","author":"Xing","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2025.101256_bb1035","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed\/refractory multiple myeloma: early experience from a phase I study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb1040","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41408-024-01114-7","article-title":"Sustained remission following finite duration bispecific antibody therapy in patients with relapsed\/refractory myeloma","volume":"14","author":"Chakraborty","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101256_bb1045","doi-asserted-by":"crossref","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb1050","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41467-020-14619-z","article-title":"CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide","volume":"11","author":"Radhakrishnan","year":"2020","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.blre.2025.101256_bb1055","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jcyt.2018.05.001","article-title":"Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy","volume":"20","author":"Murad","year":"2018","journal-title":"Cytotherapy"},{"issue":"20","key":"10.1016\/j.blre.2025.101256_bb1060","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101256_bb1065","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/s41375-022-01559-4","article-title":"CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells","volume":"36","author":"O\u2019Neal","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.blre.2025.101256_bb1070","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/nm.4431","article-title":"The activated conformation of integrin \u03b2(7) is a novel multiple myeloma-specific target for CAR T cell therapy","volume":"3","author":"Hosen","year":"2017","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb1075","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1038\/s41467-022-31810-6","article-title":"The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance","volume":"13","author":"Ferguson","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.blre.2025.101256_bb1080","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41420-024-01818-6","article-title":"Targeted immunotherapy: harnessing the immune system to battle multiple myeloma","volume":"10","author":"Xu","year":"2024","journal-title":"Cell Death Discov"},{"issue":"13","key":"10.1016\/j.blre.2025.101256_bb1085","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2025.101256_bb1090","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101256_bb1095","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2023-181857","article-title":"BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): Updated Results from a Phase 1 Study","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T03:22:27Z","timestamp":1740367347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":219,"alternative-id":["S0268960X25000013"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101256","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101256"}}